MECOM and cancer: The study found that W6134 and XY018 upregulate the expression of key inflammatory genes CXCL10 and MECOM, while genes related to TNF and IL-17 signaling pathways are significantly upregulated, indicating that W6134 and XY018 may exert their anticancer effects by modulating the aforementioned pathways, thereby influencing the growth of cancer cells.